Who Paid My Doc
Don Dizon
Medical Oncology Providence, RI Medical Doctor
NPI 1376573394 CMS profile 744193
101 Dudley St, Providence, RI 02905
General payments
$60,374
Research payments
$3,773
Ownership & investment interest
$0
Research they led as principal investigator
$226,776
Through program year 2025, Don Dizon of Providence, RI is reported in the CMS Open Payments database as having received $60,374 across 42 general payments and $3,773 in research payments paid to them. Separately, studies naming them as principal investigator received $226,776 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,467 | 11 | |
| 2024 | General | $9,636 | 8 | |
| 2023 | General | $5,621 | 4 | |
| 2023 | Research | $300 | 1 | |
| 2022 | General | $6,650 | 4 | |
| 2022 | Research | $300 | 1 | |
| 2021 | General | $12,500 | 7 | |
| 2020 | General | $10,700 | 4 | |
| 2019 | General | $8,800 | 4 | |
| 2019 | Research | $3,173 | 2 |
Beside peers
- Don Dizon
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Don Dizon were reported at $6,467. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Don Dizon | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,800 | $968 | $140–$6,658 | $163 |
| 2020 | $10,700 | $747 | $102–$5,891 | $114 |
| 2021 | $12,500 | $430 | $50–$4,098 | $132 |
| 2022 | $6,650 | $812 | $127–$4,907 | $149 |
| 2023 | $5,621 | $957 | $144–$5,248 | $160 |
| 2024 | $9,636 | $1,042 | $149–$5,650 | $164 |
| 2025 | $6,467 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
135
Drug cost
$529,950
Branded share of claims
23.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lynparza Olaparib | Brand | 20 | $323,174 | |
| Zejula Niraparib Tosylate | Brand | 12 | $205,520 | |
| Tamoxifen Citrate | Generic | 13 | $578 | |
| Prochlorperazine Maleate | Generic | 28 | $258 | |
| Ondansetron Hcl | Generic | 37 | $235 | |
| Dexamethasone | Generic | 25 | $186 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$15,009
Medicare patients
68
Services billed
190
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 75% | |
| High blood pressure | 68% | |
| Arthritis | 53% | |
| Osteoporosis | 32% | |
| Diabetes | 25% | |
| Ischemic heart disease | 22% | |
| Depression | 22% | |
| Chronic kidney disease | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ELAHERE |
|
$4,530 | — | — |
| LYNPARZA |
|
$650 | 20 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
46 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.